Zacks Research Estimates Perrigo’s Q2 Earnings (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) – Analysts at Zacks Research cut their Q2 2027 EPS estimates for Perrigo in a research report issued on Thursday, March 19th. Zacks Research analyst Team now forecasts that the company will earn $0.55 per share for the quarter, down from their previous forecast of $0.71. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s FY2028 earnings at $2.59 EPS.

Several other equities research analysts also recently issued reports on PRGO. JPMorgan Chase & Co. dropped their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Canaccord Genuity Group decreased their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Argus raised Perrigo to a “hold” rating in a report on Wednesday, January 14th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Perrigo currently has an average rating of “Hold” and an average target price of $19.33.

Perrigo Stock Down 4.2%

PRGO opened at $9.25 on Friday. Perrigo has a 12 month low of $9.23 and a 12 month high of $28.43. The company has a market cap of $1.27 billion, a PE ratio of -0.90, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The company has a current ratio of 2.76, a quick ratio of 1.63 and a debt-to-equity ratio of 1.23. The company has a 50 day moving average of $13.29 and a 200 day moving average of $16.06.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the business earned $0.93 EPS. Perrigo’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be given a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 12.5%. The ex-dividend date is Monday, March 2nd. Perrigo’s dividend payout ratio is -11.28%.

Institutional Investors Weigh In On Perrigo

Hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Perrigo by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock worth $244,634,000 after buying an additional 653,925 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after acquiring an additional 1,101,154 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its position in Perrigo by 291.9% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock worth $108,921,000 after acquiring an additional 5,828,076 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Perrigo by 2.4% in the third quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock valued at $171,367,000 after acquiring an additional 181,828 shares during the last quarter. Finally, State Street Corp increased its stake in Perrigo by 9.5% in the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock valued at $196,134,000 after acquiring an additional 637,678 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors.

Trending Headlines about Perrigo

Here are the key news stories impacting Perrigo this week:

• Neutral Sentiment: Perrigo’s most recent quarterly report (Feb 26) showed a slight revenue miss and an EPS shortfall versus last year; management set FY2026 guidance at $2.25–$2.55. The stock is trading with above-average volume and near its 1‑year low, which may amplify moves on new analyst commentary. MarketBeat Perrigo page
• Negative Sentiment: Zacks Research cut a wide set of EPS estimates across FY2026–FY2028 and lowered quarterly forecasts for Q1–Q4 2026 and multiple quarters in 2027. The firm reduced FY2026 EPS to $2.18 (from $3.00) and FY2027 EPS to $2.53 (from $3.18), reflecting a materially weaker near‑term earnings trajectory. Zacks maintained a “Hold” rating. This broad downdraft in analyst estimates is the primary catalyst for downward pressure on the stock. Zacks estimates summary

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.